Status:
COMPLETED
Study of SU011248 in Patients With Advanced Kidney Cancer
Lead Sponsor:
Pfizer
Conditions:
Carcinoma, Renal Cell
Eligibility:
All Genders
20+ years
Phase:
PHASE2
Brief Summary
To determine the objective tumor response of single-agent SU011248 at a dose of 50 mg orally once daily for 4 consecutive weeks and 2 weeks rest, repeated every 6 weeks in patients with metastatic Ren...
Eligibility Criteria
Inclusion
- Histologically proven renal cell carcinoma with metastases with a component of clear cell histology
Exclusion
- Any cellular therapy (LAK, TIL, DC), any vaccine therapy, mini-transplantation, or systemic molecular-targeting therapy for RCC.
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT00254540
Start Date
December 1 2005
End Date
February 1 2009
Last Update
February 23 2010
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Akita, Akita, Japan
2
Pfizer Investigational Site
Sapporo, Hokkaido, Japan
3
Pfizer Investigational Site
Tsukuba, Ibaragi, Japan
4
Pfizer Investigational Site
Osaka, Osaka, Japan